A. Patnaik

Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)

Imtiaz A. Malik, J. Randolph Hecht, A. Patnaik et al. · Journal of Clinical Oncology · 2005 · 83 citations

Medicine, Oncology, Pharmacology +15

A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors

A. W. Tolcher, Mace L. Rothenberg, Jordi Rodón et al. · Journal of Clinical Oncology · 2007 · 76 citations

Medicine, Oncology, Pharmacology +17

Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.

Takuya Shimizu, A. W. Tolcher, A. Patnaik et al. · Journal of Clinical Oncology · 2010 · 35 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +8

A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST)

A. W. Tolcher, A. Patnaik, E Till et al. · Journal of Clinical Oncology · 2008 · 32 citations

Medicine, Oncology, Pharmacology +17

EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies

A. Patnaik, E. Gabriela Chiorean, Anthony Tolcher et al. · Journal of Clinical Oncology · 2009 · 27 citations

Medicine, Oncology, Pharmacology +12